Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare Biotechnology

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc

Bullboard Posts

Post by OPTIMISTGOLDon May 09, 2018 12:42pm

108 Views

Post# 28005547

Echelon # 18

Echelon do not want who's go up what's his problem him?

05/09/2018 12:42 PM EDT	0.155	2,000	0.02	TSXV	079	018 Echelon Wealth Partners Inc. 150 York Street, Suite 1100, Toronto, ON M5H 3S5 416-649-4273
05/09/2018 12:36 PM EDT	0.155	1,000	0.02	TSXV	079	079
05/09/2018 12:32 PM EDT	0.155	2,000	0.02	TSXV	079	018